Medications on the Horizon
These are investigational medications in clinical trials and regulatory review that we're monitoring for possible future availability. Timelines and outcomes can change.
Arriving Soon
2026–2027These medications have filed or are expected to file for FDA approval. Publicly available data appears more mature here, but regulatory review is still ongoing.
Elamipretide
FDA ReviewAnti-AgingElamipretide injection (Forzinity)
FDA-approved (accelerated) for Barth syndrome since September 2025. Separate dry-AMD program in Phase 3. Off-label longevity use remains investigational.
Estimated timeline: 2025
Oveporexton
FDA ReviewSleepOveporexton oral tablets (Takeda)
The first oral orexin agonist — NDA accepted with Priority Review for narcolepsy type 1. PDUFA target date Q3 2026.
Estimated timeline: 2026
CagriSema
FDA SubmissionWeight LossSemaglutide + Cagrilintide combination injection
The next evolution of GLP-1 therapy — combining semaglutide with an amylin analog for best-in-class weight loss.
Estimated timeline: 2027
Clascoterone Solution
FDA SubmissionHair LossClascoterone 7.5% topical solution
Clascoterone is FDA-approved for acne and is being studied for hair-related use. Varus currently offers information and waitlist updates only.
In Development
2027–2028Phase 3 trials are complete or ongoing. Findings are still being evaluated, and approval is not guaranteed.
Retatrutide
Phase 3Weight LossRetatrutide injection (triple agonist)
A triple GIP/GLP-1/glucagon agonist in Phase 3 trials — investigational only, available exclusively through Lilly clinical trials.
Estimated timeline: 2027
Survodutide
Phase 3Weight LossSurvodutide injection (Boehringer Ingelheim)
A dual GLP-1/glucagon agonist with Breakthrough Therapy designation for weight loss and MASH.
Estimated timeline: 2027
Seltorexant
Phase 3SleepSeltorexant oral tablets (J&J)
A selective orexin-2 receptor antagonist in Phase 3 for adjunctive treatment of major depressive disorder with insomnia symptoms. Not a dual orexin receptor antagonist (DORA).
Estimated timeline: 2028
VDPHL01 (Veradermics)
Phase 3Hair LossExtended-release oral minoxidil (Veradermics)
An extended-release oral minoxidil designed specifically for hair loss — backed by Eli Lilly investment.
Estimated timeline: 2028
Earlier Stage
2028+Earlier-stage compounds we are monitoring. The science is still evolving, and timelines and outcomes remain uncertain.
HU6
Phase 2Weight LossHU6 oral capsules (Rivus Pharmaceuticals)
Fat-only weight loss — HU6 targets fat tissue while preserving 100% of muscle mass.
Estimated timeline: 2028
Bimagrumab
Phase 2Weight LossBimagrumab injection (Eli Lilly)
An anti-myostatin antibody that builds muscle while losing fat — the ideal GLP-1 companion.
Estimated timeline: 2028
PP405 (Pelage Pharmaceuticals)
Phase 2Hair LossPP405 topical (UCLA / Google-funded)
A non-hormonal hair loss treatment targeting melanocyte progenitor cells — funded by Google Ventures.
Estimated timeline: 2029
Pipeline information is based on publicly available clinical trial data and company announcements. Estimated timelines are subject to change. Varus does not guarantee availability of any pipeline treatment. Join the waitlist to be notified when treatments become available through our platform.